AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$LUNG

French Glendon E. III sold $87K of LUNG

French Glendon E. III (President and CEO) sold 56,149 shares of Pulmonx Corp (LUNG) at an average of $1.55 ($1.54–$1.57) across 3 trades over 2026-06-01 to 2026-06-02.

Original reporting
SEC EDGAR · French Glendon E. III
Published Jun 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The modest insider sell may trigger short‑term price softness but is unlikely to affect long‑term fundamentals.

02

Market read

Provides fresh insider transaction data for traders monitoring LUNG.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions; this filing reports a recent sale by Pulmonx's CEO.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

President and CEO Glendon E. French III sold 56,149 shares for $86,874.79 in a Form 4 filing.

Expected impact

likely slight downward pressure as investors interpret the CEO's sell as a weak signal

Evidence & confidence

The sale size (~$87k) is small relative to market cap, but insider sales by a CEO are closely watched and can prompt short-term price dips.

Market effects

Sector

Minimal impact on the broader medical device sector; the transaction is company‑specific.

Regional

Negligible effect on regional markets.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move and not indicative of future performance.

Key entities

  • Company
    Pulmonx Corp

    Medical device company listed on NASDAQ under ticker LUNG.

  • Executive
    Glendon E. French III

    President and CEO of Pulmonx Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LUNG insider trading history →

Related articles

JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 29
$LUNGMed

Pulmonx Reports Second Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon

SEC EDGAR 8-K3 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min